Hospital pharmacists awarded 3.6% pay rise The Guild of Healthcare Pharmacists said the pay award does not go far enough in reversing the below-inflation awards seen in previous years.…
Funding gap: economic analysis paints dire picture of community pharmacy’s sustainability An independent economic analysis has revealed that the cost of delivering community pharmacy NHS services in England far outstrips the funding available, even after the uplift agreed in the latest contract negotiations.…
Next Welsh government urged to agree new community pharmacy funding formula In its manifesto published ahead of the 2026 Senedd elections, Community Pharmacy Wales said the next Welsh government must ensure the future of a viable and sustainable community pharmacy network.…
Community Pharmacy Scotland announces first part of funding deal for 2025/2026 Under the funding deal accepted by Community Pharmacy Scotland, in 2025/2026, the guaranteed minimum for reimbursement will increase to £120m.…
Medicines optimisation teams need to showcase their value to withstand ICB funding cuts With integrated care boards soon to have lost 65% of their funding over two years, now is the time for medicines optimisation teams to ‘be noisy’ about their work.…
Chief pharmacists call for medicines leadership to be ‘fundamental component’ of strategic commissioning system In a letter to NHS England, four integrated care board chief pharmacists said that they must shape and lead on medicines at a time of NHS change.…
No increase in NHS prescription fees for the first time in three years The government has announced that the single item prescription charge for 2025/2026 will remain at £9.90.…
NICE reverses draft guidance to recommend targeted therapy for patients with advanced bowel cancer The National Institute for Health and Care Excellence said the treatment should be available on the NHS after the manufacturer provided additional clinical evidence.…
NHS England sets target to save £1bn on medicines by 2029 Board papers published in March 2025 said that using “commercial capabilities” had realised close to £500m in medicines savings in 2023/2024.…
NICE recommends capivasertib for advanced breast cancer Clinical trial results revealed that capivasertib, taken with fulvestrant, can provide advanced breast cancer patients with an additional four months before their cancer progresses.…
